The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q).

Soumis par MedicsLab le lun 02/03/2020 - 12:26

Introduction The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q) created a research infrastructure to recruit, characterize, and track disease progression in individuals at risk of dementia. Methods:CIMA-Q established standardized clinical, neuropsychological, neuroimaging, blood (plasma, serum, RNA, genomic DNA), cryopreserved peripheral blood mononuclear cells, and cerebrospinal fluid collection protocols. These data and biological materials are available to the research community.

A multiomics approach to heterogeneity in Alzheimer's disease: focused review and roadmap

Soumis par MedicsLab le lun 02/03/2020 - 12:21

Alzheimer’s disease is a complex, multifactorial pathology that manifests itself along a continuum of conditions, ranging from asymptomatic, to mild cognitive impairment (MCI), to dementia (specifically Alzheimer’s disease dementia). Trials of disease-modifying therapies remain unsuccessful, and these persistent failures have been attributed to (i) intervention late in the disease process (i.e. symptomatic stage), by which time extensive irreversible damage has accrued; and (ii) lack of precision intervention targets in a multifactorial condition.